These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12482730)

  • 1. Drugs targeting functional bowel disorders: insights from animal studies.
    Sanger GJ; Hicks GA
    Curr Opin Pharmacol; 2002 Dec; 2(6):678-83. PubMed ID: 12482730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ion channels as targets for treatment of gastrointestinal motility disorders.
    Farrugia G
    Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():135. PubMed ID: 18924455
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
    Camilleri M
    Clin Pharmacol Ther; 2012 Jan; 91(1):44-59. PubMed ID: 22071696
    [No Abstract]   [Full Text] [Related]  

  • 4. Tachykinin receptors as drug targets for motility disorders.
    Hoogerwerf WA; Sarna SK
    Dig Dis; 2006; 24(1-2):83-90. PubMed ID: 16699266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders.
    Peeters TL
    Curr Opin Pharmacol; 2006 Dec; 6(6):553-8. PubMed ID: 17011824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upper gastrointestinal promotility drugs: not all uniform?
    Brun R; Kuo B
    Indian J Gastroenterol; 2009; 28(4):123-5. PubMed ID: 19937420
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prokinetic drugs in gastroenterology].
    Galmiche JP; Bruley des Varannes S; Le Bodic L
    Gastroenterol Clin Biol; 1991; 15(2 ( Pt 3)):T7-10. PubMed ID: 2065903
    [No Abstract]   [Full Text] [Related]  

  • 8. The enteric nervous system III: a target for pharmacological treatment.
    Hansen MB
    Pharmacol Toxicol; 2003 Jul; 93(1):1-13. PubMed ID: 12828568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of drugs for gastrointestinal motor disorders: translating science to clinical need.
    Sanger GJ; Alpers DH
    Neurogastroenterol Motil; 2008 Mar; 20(3):177-84. PubMed ID: 18257767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial cells of Cajal as targets for pharmacological intervention in gastrointestinal motor disorders.
    Huizinga JD; Thuneberg L; Vanderwinden JM; Rumessen JJ
    Trends Pharmacol Sci; 1997 Oct; 18(10):393-403. PubMed ID: 9357324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prokinetics and fundic relaxants in upper functional GI disorders.
    Tack J
    Curr Opin Pharmacol; 2008 Dec; 8(6):690-6. PubMed ID: 18940266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are We Close to Targeting Enteric Glia in Gastrointestinal Diseases and Motility Disorders?
    Gulbransen BD; Christofi FL
    Gastroenterology; 2018 Aug; 155(2):245-251. PubMed ID: 29964042
    [No Abstract]   [Full Text] [Related]  

  • 13. Evolving concepts in functional gastrointestinal disorders: promising directions for novel pharmaceutical treatments.
    Hunt RH; Tougas G
    Best Pract Res Clin Gastroenterol; 2002 Dec; 16(6):869-83. PubMed ID: 12473296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological treatment of functional bowel disorders: any light at the end of the tunnel?
    Boeckxstaens GE
    Curr Opin Pharmacol; 2008 Dec; 8(6):669-70. PubMed ID: 18835367
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic approaches towards the treatment of gastroinstestinal disorders.
    Collingwood S; Witherington J
    Drug News Perspect; 2007 Mar; 20(2):139-44. PubMed ID: 17440638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical Evaluation of Animal Models of Gastrointestinal Disorders.
    Johnson AC; Greenwood-Van Meerveld B
    Handb Exp Pharmacol; 2017; 239():289-317. PubMed ID: 28176046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gastrointestinal motility disorders and drugs: opioids, calcium antagonists, nitrates, peptides, prostaglandins and 5-hydroxytryptaminergic drugs (part II)].
    Jovanović-Mićić D; Samardzić R; Beleslin B
    Srp Arh Celok Lek; 1994; 122(3-4):88-92. PubMed ID: 17972818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.
    Katzka DA; Loftus EV; Camilleri M
    Clin Pharmacol Ther; 2012 Sep; 92(3):306-20. PubMed ID: 22828717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases.
    Sanger GJ
    Drug Discov Today; 2008 Mar; 13(5-6):234-9. PubMed ID: 18342799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New pharmacologic therapies in gastrointestinal disease.
    Wallace JL; Ferraz JG
    Gastroenterol Clin North Am; 2010 Sep; 39(3):709-20. PubMed ID: 20951926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.